PIRS: Initiating coverage of Pieris Pharmaceuticals, Inc.; Anticalin® is the new antibody
Pieris Pharmaceuticals is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs. The company's development plans focuses on two primary pillars, respiratory diseases and IO. The company's respiratory Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain, thereby inhibiting the actions of IL-4 and IL-13, two cytokines (small proteins mediating signaling between cells within the human body) known to be key mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. The company's PRS-080 is a polyethylene glyco, conjugated Anticalin protein that binds to hepcidin, a natural regulator of iron levels in the blood.
Zacks Investment Research is a Chicago based firm with over 30 years of experience in providing institutional and individual investors with the analytical tools and financial information necessary to the success of their investment process.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.